Indapamide clinical trials
Indapamide is named as an intervention in 2 current clinical trials in our Denmark and Switzerland registers. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Lars Rejnmark (1). The most-studied condition is Hypoparathyroidism Post-surgical. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Indapamide is approved
All regulators →Of the three regulators tracked here, the first to approve Indapamide was the US, on 6 Jul 1983. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Indapamide
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Indapamide works
All drug targets →- Thiazide-sensitive sodium-chloride cotransporter inhibitor InhibitorTarget: SLC12A3 solute carrier family 12 member 3ChEMBL only
- Essential hypertensionPhase 3
- Multiple sclerosis symptom measurementPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL406, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7203, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Indapamide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 2 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Indapamide
- ATC code
- C03BA11
- ChEMBL
- CHEMBL406
- DrugBank
- DB00808
- PubChem CID
- 3702
- CAS number
- 26807-65-8
- FDA UNII
- F089I0511L
- Wikidata
- Q1078392
- Wikipedia
- Indapamide
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Indapamide
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism
NCT07034677 · Hypoparathyroidism Post-surgical
|
Phase 4 | Recruiting | Lars Rejnmark | Denmark |
|
Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention
NCT06111885 · ClinicalTrials.gov ↗ · Kidney Stone
|
Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | Switzerland |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Indapamide in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Indapamide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)
2026-525260-18-00 · Nervous System Diseases
|
Phase 2 | Ongoing | Amsterdam UMC Stichting | Netherlands |
Indapamide across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
2 single-substance products containing Indapamide on the HPRA medicines list.
- Icorvida SR 1.5mg Prolonged-release TabletsKRKA, d.d., Novo mesto · PA1347/022/001 · Marketed
- Natrilix SR 1.5 mg, prolonged-release film-coated tabletsLes Laboratoires Servier · PA0568/005/001 · Marketed
Supply shortages
- Preterax N 2,5 mg/ 0,625 mg FilmtablettenGermany (BfArM) · Other reason · 23 Oct 2026 to 20 Dec 2026
- Preterax N 2,5 mg/ 0,625 mg FilmtablettenGermany (BfArM) · Other reason · 23 Oct 2026 to 20 Dec 2026
- BiPreterax N 5 mg/ 1,25 mg FilmtablettenGermany (BfArM) · Other reason · 6 Nov 2026 to 22 Jan 2027
- Perindopril/Indapamid-ratiopharm T 2,5 mg/0,625 mg FilmtablettenGermany (BfArM) · Other reason · 28 Aug 2026 to 15 Dec 2026
Conditions studied with Indapamide
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Lars Rejnmark | 1 |
| Insel Gruppe AG, University Hospital Bern | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Denmark | 1 | 1 |
| Clinical trials in Switzerland | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Indapamide trials
How many clinical trials are testing Indapamide?
2 current trials in our Denmark and Switzerland registers name Indapamide as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Indapamide trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 1 with sites in Denmark and 1 with sites in Switzerland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Indapamide clinical trials?
Lars Rejnmark (1) and Insel Gruppe AG, University Hospital Bern (1). The number in brackets is how many trials each organisation leads.
Is Indapamide licensed in Ireland?
Yes. The HPRA medicines list includes 2 single-substance products containing Indapamide, for example Icorvida SR 1.5mg Prolonged-release Tablets (KRKA, d.d., Novo mesto). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Indapamide shortage?
The registers we track list 4 entries for Indapamide: 4 German notices. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Indapamide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Indapamide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Indapamide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.